Takeda Pharmaceutical Company Limited TAK
Set alert
As of Nov 2, 2:26 PM ET
- YTD
- +33.90%
- 1 year
- +55.32%
- Open
- 20.88
- Prev close
- 20.91
- Mkt cap
- 66.69B
- Vol
- 1.59M
- Avg vol
- 2.73M
- EPS
- 0.07
- P/E
- 298.21
- Div yield
- 2.41%
More statistics
- Low
- 20.78
- High
- 21.17
- Forward P/E
- 39.48
- Beta
- 0.10
- Short ratio
- 1.21
- Inst. own
- 3.32%
- Dividend
- 0.62
- Ex-div date
- Mar 30, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 18.78
- 200-d avg
- 17.53
- 1y target
- 23.08
5D chart
Events in this range
- Oct 29, 2026Earnings: 0.3852; estimate 0.145; surprise 165.66%
Signals (68)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 12:25 PM | 2 hours ago |
| SMA: Bearish | Nov 2, 12:05 PM | 2 hours ago |
| MACD: Buy Signal | Nov 2, 11:25 AM | 3 hours ago |
| SMA: Bullish | Nov 2, 11:20 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 11:10 AM | 3 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 4 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 10:00 AM | 4 hours ago |
| MACD: Buy Signal | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:40 AM | 4 days ago |
| RSI: Oversold | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 3:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 5 days ago |
| RSI: Oversold | Oct 28, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 5 days ago |
| RSI: Oversold | Oct 28, 2:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:00 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 6 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 6 days ago |
News
3 days ago seekingalpha.com
Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow
Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but…
3 days ago marketbeat.com
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline…
4 days ago benzinga.com
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical Co Ltd (NYSE:TAK) on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the consensus of 31 cents.
4 days ago benzinga.com
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.
4 days ago seekingalpha.com
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
4 days ago benzinga.com
Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript
Takeda Pharmaceutical Co (NYSE:TAK) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is…
-
4 days ago benzinga.com
Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
-
4 days ago benzinga.com
Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.31 by 54.84 percent. This is a 20 percent increase over earnings of…
4 days ago businesswire.com
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of…
-
1 week ago benzinga.com
Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements
Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual…
1 week ago businesswire.com
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D…
2 weeks ago benzinga.com
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
-
2 weeks ago benzinga.com
Takeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC Complication Risk By Nearly 70%
Takeda ((TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF…
2 weeks ago businesswire.com
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to…
2 weeks ago benzinga.com
Ascentage Pharma Stock Could More Than Double: Analyst
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
-
2 weeks ago benzinga.com
Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA)…
2 weeks ago businesswire.com
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1…
2 weeks ago businesswire.com
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.
2 weeks ago seekingalpha.com
Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline
Takeda gets its prior buy rating reaffirmed. Positive factors are recent drug approval, robust future pipeline, global reach, and an investment-grade rating. TAK serves several clinical areas,…
1 month ago defenseworld.net
Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and ProPhase Labs (NASDAQ: PRPH - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
-
1 month ago benzinga.com
Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete…
1 month ago defenseworld.net
Takeda Pharmaceutical (NYSE:TAK) vs. RYTHM (NASDAQ:RYM) Financial Survey
RYTHM (NASDAQ: RYM - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on…
1 month ago businesswire.com
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational,…
-
1 month ago benzinga.com
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent…
1 month ago businesswire.com
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.
1 month ago reuters.com
Roche proposes former Takeda CEO for board seat
Roche on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals , for election to the Swiss company's board of directors at its AGM next March.
1 month ago businesswire.com
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical…
1 month ago benzinga.com
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.
1 month ago businesswire.com
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR)…
1 month ago reuters.com
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
1 month ago benzinga.com
Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
Takeda Pharmaceutical Co (NYSE:TAK) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
1 month ago defenseworld.net
Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both healthcare companies, but which is the superior business? We will…
1 month ago seekingalpha.com
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pillResults from nearly 3,000…
-
1 month ago benzinga.com
Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist,…
2 months ago benzinga.com
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
-
2 months ago benzinga.com
Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1)Landmark Phase 3 Studies Demonstrated…
2 months ago benzinga.com
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
2 months ago benzinga.com
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.
2 months ago benzinga.com
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
Takeda secured FDA approval for ORZEYFUL, a first-in-class oral orexin treatment for adults with narcolepsy type 1.
-
2 months ago benzinga.com
Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on PlaceboAs a…
-
3 months ago benzinga.com
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or…
-
3 months ago benzinga.com
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950…
-
3 months ago benzinga.com
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
-
3 months ago benzinga.com
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 7.69 percent decrease over earnings of…
3 months ago benzinga.com
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clearance ahead of its planned FDA filing.
-
3 months ago benzinga.com
Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance
New data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe…
3 months ago benzinga.com
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships
The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals image credit: Bamboo Works Key
-
3 months ago benzinga.com
Reported Sunday, Takeda To Invest Up To $30M In Indonesia Plasma Ecosystem As Part Of Landmark Healthcare Collaboration With Indonesian Government, Including National Plasma Donation Network Pilot
Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased InitiativeTakeda Will Initially Invest…
4 months ago benzinga.com
Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine
Takeda and Insilico Medicine launch a strategic AI drug discovery collaboration to identify next-generation therapies.